AR and prostate adenocarcinoma: In this study, we identified aberrant Wnt/β-catenin signaling activation in hARtg+ prostatic tumor cells, uncovering the regulatory mechanisms underlying AR action in atypical cells to progress to prostatic adenocarcinomas.